And importantly, the large 2025 Phase 3 GLP-1 Parkinsons trial failed to show meaningful disease modification compared to placebo
Codeage Liposomal TUDCA+ features tauroursodeoxycholic acid (TUDCA), a bile acid compound, combined with N-acetyl-L-cysteine (NAC)
they are not FDA-approved for general consumer use, retail sale or recreational selfadministration and are dispensed exclusively through licensed pharmacies to patients under active clinical care
Low thyroid can also lead to decreased blood flow in the brain, preventing brain cells from getting the oxygen and nutrients they need
Furthermore, it has emerged that supporting or inducing mitochondrial bioenergetics, stress responses, mitophagy, and other adaptation mechanisms is critical to mediate some of the health or longevity benefits observed in studies using NAD + modulation strategies
Available from Smith, A